Robert Chisholm joins Anavex's board, as CFO David Tousley departs
This article was originally published in Scrip
Robert Chisholm, a finance and administration executive with more than 25 years' experience, has joined Anavex's board of directors to advise on corporate finance and strategic business initiatives. Mr Chisholm is currently an officer and partner of Emprise Capital Corp, a company which gives advice on managing corporate finances. Anavex has also appointed its president, Harvey Lalach, as interim chief financial officer, as current CFO David Tousley stands down.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.